CARsgen Therapeutics Holdings Limited (CARsgen) reported that preliminary data from its investigator-initiated trial (IIT) CT041-CG4010 of satricabtagene autoleucel (satri-cel, CT041) in China have been selected for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The abstract will be released on the ESMO website at 00:05 CEST on 19 October 2026.
Patient enrolment for the IIT, which evaluates satri-cel as consolidation therapy after adjuvant treatment in locally advanced gastric or gastroesophageal junction cancer (G/GEJA), began in May 2025. As of the announcement date, none of the treated participants have experienced post-operative cancer recurrence or metastasis.
Satri-cel is the world’s first approved chimeric antigen receptor T-cell (CAR T) therapy targeting Claudin18.2-positive solid tumors. In June 2026, China’s National Medical Products Administration (NMPA) cleared satri-cel for Claudin18.2-positive, HER2-negative advanced G/GEJA in patients who had failed at least two prior treatment lines.
Beyond the current IIT, CARsgen is expanding satri-cel’s clinical footprint: 1. A Phase I trial in China for pancreatic cancer adjuvant therapy (NCT05911217). 2. An IIT assessing consolidation after adjuvant therapy in resected G/GEJA (NCT06857786, current study). 3. An IIT evaluating sequential therapy following first-line treatment for G/GEJA (NCT07179484).
CARsgen has developed end-to-end capabilities covering target discovery, pre-clinical research, clinical development and commercial-scale production of CAR T-cell therapies aimed at hematologic malignancies, solid tumors and autoimmune diseases.
The company cautioned that development and potential commercialization of satri-cel outside mainland China remain subject to inherent clinical, regulatory and market uncertainties. Shareholders and prospective investors are advised to exercise caution when dealing in CARsgen-B shares.
Comments